Singapore Markets close in 2 hrs 17 mins

Kyowa Kirin Co., Ltd. (KYKOF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
20.870.00 (0.00%)
At close: 09:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close20.87
Open20.87
Bid0.00 x 0
Ask0.00 x 0
Day's range20.87 - 20.87
52-week range20.87 - 28.73
Volume43
Avg. volume460
Market cap11.217B
Beta (5Y monthly)0.11
PE ratio (TTM)26.02
EPS (TTM)0.80
Earnings dateN/A
Forward dividend & yield0.41 (1.84%)
Ex-dividend date29 Jun 2023
1y target estN/A
  • Business Wire

    MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

    SAN DIEGO & TOKYO, December 05, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that after receiving the most recent guidance from a late November meeting with the U.S. Food and Drug Administration (FDA), the companies are discontinuing glob

  • Business Wire

    Grünenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio

    AACHEN, Germany & TOKYO, November 24, 2022--Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio. The Joint Venture Collaboration comprises 13 brands across 6 therapeutic

  • Business Wire

    MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022

    SAN DIEGO & TOKYO, November 03, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that three abstracts highlighting data and information from the clinical development program evaluating the intermittent dosing of zandelisib, an investigational